Yet, the combination of anti-PD-L1 with antibodies directed against vascular endothelial growth factor (VEGF), which sustains tumor angiogenesis and mediates immunosuppression in the TME, succeeded in a phase III trial. Here, VEGFA is linked to neoplasm.